Halozyme Therapeutics came out with a quarterly loss of $0.01 per share versus Wall Street's estimate of a loss of $0.02. This compares to earnings of $0.85 per share a year ago. This quarterly report represents an earnings surprise of 50%. Last quarter, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.19. Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Halozyme posted revenue of $60.23 million for the quarter ended December 2018. "We have a broad enhanced pipeline with our partners," said Helen Torley, CEO of Halozyme in a conference call. "By the end of 2019, we project this will include three products in Phase 3 clinical testing and nine products in Phase 1 clinical testing. With those key takeaways, let me provide some additional details on our recent progress and results. Earlier this month, we announced a new collaboration with argenx, a development-stage biotechnology company with a focus on severe autoimmune diseases and other therapeutic areas."
The 50-day moving average for HALO moved above the 200-day moving average on April 09, 2024. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where HALO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 01, 2024. You may want to consider a long position or call options on HALO as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HALO just turned positive on May 01, 2024. Looking at past instances where HALO's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HALO advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .
HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
HALO moved below its 50-day moving average on April 12, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HALO crossed bearishly below the 50-day moving average on April 18, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for HALO entered a downward trend on April 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (59.524) is normal, around the industry mean (10.224). P/E Ratio (18.714) is within average values for comparable stocks, (114.157). HALO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.464). HALO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (6.361) is also within normal values, averaging (237.903).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology